Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18998887 | 0.94 | TDP1 (0.46) | TDP1RAPGEF4ALDH1A1LMNATSHR | |
| SCHEMBL21283087 | 0.84 | TDP1 (0.38) | TDP1RAPGEF4ALDH1A1LMNATSHR | |
| SCHEMBL801749 | 0.84 | TDP1 (0.38) | TDP1RAPGEF4ALDH1A1LMNATSHR | |
| SCHEMBL12369335 | 0.84 | RAPGEF4 (0.44) | TDP1RAPGEF4ALDH1A1LMNATSHR | |
| SCHEMBL12369336 | 0.84 | RAPGEF4 (0.44) | TDP1RAPGEF4ALDH1A1LMNATSHR | |
| SCHEMBL10024341 | 0.82 | TDP1 (0.55) | TDP1ALDH1A1LMNATSHRTHRB | |
| SCHEMBL11408555 | 0.80 | RAPGEF4 (0.39) | TDP1RAPGEF4ALDH1A1LMNATSHR | |
| SCHEMBL12128223 | 0.79 | PIK3CB (0.36) | TDP1ALDH1A1LMNATHRBHTT | |
| SCHEMBL11404383 | 0.78 | TDP1 (0.46) | TDP1ALDH1A1LMNATSHRTHRB | |
| SCHEMBL12128222 | 0.76 | GAA (0.38) | TDP1ALDH1A1KMT2AHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-11130764-B2 | Analogs of vincamine and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3245213-B1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL MYERS SQUIBB CO (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| WO-2003035057-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2003-05-01 | — | — | WO | disclosed |
| EP-0690055-B1 | Stereoselective process for making endo-tropanamine and like compounds | LILLY CO ELI (US) | 2001-11-14 | — | — | EP | disclosed |
| US-5625065-A | Stereoselective process for making endo-tropanamine and like compounds | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0690055-A1 | Stereoselective process for making endo-tropanamine and like compounds | ELI LILLY AND COMPANY (US) | 1996-01-03 | — | — | EP | disclosed |
| US-4196142-A | 2-Chloro-n-isopropyl-3,5-disubstituted or 3,4,5-trisubstitutes lower alkyl acetanilides as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885RAPGEF4 4132/4885ALDH1A1 4827/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885RAPGEF4 4132/4885ALDH1A1 4827/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885RAPGEF4 4132/4885ALDH1A1 4827/4885 |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | PREP, PEPD, DPP4 | TDP1 1939/4885RAPGEF4 4375/4885ALDH1A1 1180/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885RAPGEF4 4132/4885ALDH1A1 4827/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885RAPGEF4 4132/4885ALDH1A1 4827/4885 |
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | METAP1, METAP2, ENPEP | TDP1 2260/4885RAPGEF4 4734/4885ALDH1A1 1430/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | TDP1 792/4885RAPGEF4 3524/4885ALDH1A1 4199/4885 |
| US-11130764-B2 | Analogs of vincamine and uses thereof | GLS, GLS2, VAT1 | TDP1 1393/4885RAPGEF4 891/4885ALDH1A1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.